Abstract:Ferroptosis is a non-apoptotic form of cell death resulting from the iron-dependent accumulation of lipid peroxides. Colorectal cancer (CRC) cells accumulate high levels of intracellular iron and reactive oxygen species (ROS) and are thus particularly sensitive to ferroptosis. The compound (S)-RSL3 ([1S,3R]-RSL3) is a commonly used ferroptosis inducing compound that is currently characterized as a selective inhibitor of the selenocysteine containing enzyme (selenoprotein) Gluathione Peroxidase 4 (GPx4), an enzyme that utilizes glutathione to directly detoxify lipid peroxides. However, through chemical controls utilizing the (R) stereoisomer of RSL3 ([1R,3R]-RSL3) that does not bind GPx4, combined with inducible genetic knockdowns of GPx4 in CRC cell lines, we revealed that GPx4 dependency does not always align with (S)-RSL3 sensitivity, questioning the current characterization of GPx4 as the central regulator of ferroptosis. Utilizing affinity pull-down mass spectrometry with chemically modified (S)-RSL3 probes we discovered that the effects of (S)-RSL3 extend far beyond GPx4 inhibition, revealing that (S)-RSL3 is a broad and non-selective inhibitor of selenoproteins. To further investigate the therapeutic potential of broadly disrupting the selenoproteome as a therapeutic strategy in CRC, we employed additional chemical and genetic approaches. We found that the selenoprotein inhibitor auranofin, an FDA approved gold-salt, chemically induced oxidative cell death and ferroptosis in both in-vitro and in-vivo models of CRC. Consistent with these data, we found that AlkBH8, a tRNA-selenocysteine methyltransferase required for the translation of selenoproteins, is essential for the in-vitro growth and xenograft survival of CRC cell lines. In summary, these findings recharacterize the mechanism of action of the most commonly used ferroptosis inducing molecule, (S)-RSL3, and reveal that broad inhibition of selenoproteins is a promising novel therapeutic angle for the treatment of CRC.

Ribosome stalling during selenoprotein translation exposes a ferroptosis vulnerability in cancer

Ribosome stalling during selenoprotein translation exposes a ferroptosis vulnerability

Multienzyme-like Reactivity Cooperatively Impairs Glutathione Peroxidase 4 and Ferroptosis Suppressor Protein 1 Pathways in Triple-Negative Breast Cancer for Sensitized Ferroptosis Therapy.

LRP8-mediated selenocysteine uptake is a targetable vulnerability in MYCN-amplified neuroblastoma

Targeting GPX4 in human cancer: Implications of ferroptosis induction for tackling cancer resilience

Targeting Ferroptosis for Cancer Therapy: Exploring Novel Strategies from Its Mechanisms and Role in Cancers

Selenoprotein P expression in glioblastoma as a regulator of ferroptosis sensitivity: preservation of GPX4 via the cycling-selenium storage

Metabolism of Selenium, Selenocysteine, and Selenoproteins in Ferroptosis in Solid Tumor Cancers

Recharacterization of RSL3 reveals that the selenoproteome is a druggable target in colorectal cancer

mTORC1 couples cyst(e)ine availability with GPX4 protein synthesis and ferroptosis regulation

Regulation of Ferroptotic Cancer Cell Death by GPX4

Selenium Utilization by GPX4 Is Required to Prevent Hydroperoxide-Induced Ferroptosis

The ferroptosis inducing compounds RSL3 and ML162 are not direct inhibitors of GPX4 but of TXNRD1

Oncogenic RAS signaling suppresses ferroptosis via transcriptional upregulation of GCH1

Targeting GPX4 in ferroptosis and cancer: chemical strategies and challenges

Breast cancer secretes anti-ferroptotic MUFAs and depends on selenoprotein synthesis for metastasis

Ferroptosis‐modulating small molecules for targeting drug‐resistant cancer: Challenges and opportunities in manipulating redox signaling

Sensitization of cancer cells to ferroptosis coincident with cell cycle arrest

Dysregulation of cellular iron predisposes chemotherapy resistant cancer cells to ferroptosis

Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones

USP8-governed GPX4 Homeostasis Orchestrates Ferroptosis and Cancer Immunotherapy